Danilo Verge

Danilo Verge, MD MBA ~ Astra Zeneca

Dr. Danilo Verge is the Vice President for Cardiovascular and Metabolic Disease (CVMD) in Global Medical Affairs at Astra Zeneca, responsible for all medical activities related to diabetes, cardiovascular and renal disease. He previously worked at Novo Nordisk for 16 years, where he most recently led the Diabetes and Obesity Medical Affairs team in their US affiliate.  He has also held international positions at Novo Nordisk (headquarters in Copenhagen, Denmark, regional European office in Zurich and in the Spanish affiliate in Madrid) and has been involved in the development of many of its antidiabetic compounds, including insulin analogs and liraglutide.

Dr. Verge obtained his Bachelor of Science at St. Lawrence University in Canton, New York, and his medical degree at the University of Buenos Aires, Argentina. He also holds a Master of Business Administration degree from SIMI Copenhagen Business School (CBS) in Denmark. Dr. Verge is a member of the American Diabetes Association and the European Association for the Study of Diabetes. He has published a review on cardiovascular aspects of GLP-1R agonists, two reviews in the area of insulin analogues and is an occasional contributor to Pharmaceutical Marketing Europe, a specialized industry magazine.

Please feel free to share this...